Compare Abbott Laboratories (ABT) vs Arqit Quantum Inc (ARQQ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Arqit Quantum Inc — how do they compare? Abbott Laboratories trades at $95.62 (market cap $166.94B), while Arqit Quantum Inc trades at $19.6 (market cap $345.44M). The key difference: Abbott Laboratories is far larger — about 483.3× Arqit Quantum Inc's market cap, and Abbott Laboratories pays a 2.63% dividend while Arqit Quantum Inc pays none. Which is the better fit depends on your goals.
| ABT | ARQQ | |
|---|---|---|
Market Cap | $166.94B | $345.44M |
Sector | Health | Technology |
52-Week High | $136.62 | $58.27 |
52-Week Low | $82.57 | $11.78 |
Enterprise Value | $193.69B | $318.75M |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
ARQQ trades at $22.13, down 5.89% today, with a bullish technical signal supported by moving averages. The company reported $530K revenue for 2025 but significant losses of -$35.34M net income, with negative margins and high P/S ratio of 319.93. Recent news highlights quantum security contract wins and 829% YoY revenue growth in H1 FY26, suggesting potential turnaround momentum despite current financial challenges.
Outlook remains speculative with high execution risk; substantial revenue growth and government/telecom deals offer upside, but persistent losses and negative ROE (-181%) pose significant shareholder value concerns. Analyst consensus is divided with 50% buy rating, indicating cautious optimism amid financial instability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Arqit Quantum Inc
Arqit Quantum provides advanced cybersecurity software that uses symmetric key agreement technology. Its solutions protect networked devices and data against current and future cyber threats, including quantum attacks.
Read more on ARQQ →
